Alzheimer's disease

After yet another PhIII Alzheimer’s failure, experts try to map a path out of the wrecking field
After yet another PhIII Alzheimer’s failure, experts try to map a path out of the wrecking field
Endpoints
FDA
Alzheimer's disease
R&D
NIH
biomarkers
Flag link:
vTv therapeutics Alzheimer's Drug Fails to Reach Primary Endpoints in Ph III study
vTv therapeutics Alzheimer's Drug Fails to Reach Primary Endpoints in Ph III study
CP Wire
vTv Therapeutics
azeliragon
Alzheimer's disease
Flag link:
vTv therapeutics Alzheimer's Drug Fails to Reach Primary Endpoints in Ph III study
vTv Therapeutics
azeliragon
Alzheimer's disease
Flag link:
What if we have got it wrong on Alzheimer's?
What if we have got it wrong on Alzheimer's?
Sydney Herald
Alzheimer's disease
Pfizer
anti-amyloid
Flag link:
Americans With Alzheimer's Now Number 5.7 Million
Americans With Alzheimer's Now Number 5.7 Million
Forbes
Alzheimer's disease
Flag link:
Prothena, Celgene ink neuro R&D pact potentially worth $2B+
Prothena, Celgene ink neuro R&D pact potentially worth $2B+
Fierce Biotech
Prothena
Celgene
R&D
TDP-43
anti-tau antibodies
Alzheimer's disease
Flag link:
Denali Therapeutics starts testing novel approach to fight Alzheimer’s
Denali Therapeutics starts testing novel approach to fight Alzheimer’s
GoinPharma
Denali Therapeutics
Alzheimer's disease
DNL747
Teva Pharmaceutical
Flag link:
Alzheimer's Costs Reach $277 Billion
Alzheimer's Costs Reach $277 Billion
Forbes
Alzheimer's disease
healthcare costs
Flag link:
Alzheon Files for IPO to Fund Studies of Amyloid Alzheimer’s Drug
Alzheon Files for IPO to Fund Studies of Amyloid Alzheimer’s Drug
Xconomy
Alzheon
Alzheimer's disease
IPOs
ALZ-801
Flag link:
With $69M Deal, AbbVie Turns to Voyager for an Alzheimer’s Gene Therapy
With $69M Deal, AbbVie Turns to Voyager for an Alzheimer’s Gene Therapy
Xconomy
AbbVie
Voyager Therapeutics
gene therapy
Alzheimer's disease
Flag link:
Biogen’s key Alzheimer’s disease drug is facing potential signs of trouble
Biogen’s key Alzheimer’s disease drug is facing potential signs of trouble
Marketwatch
Biogen
Alzheimer's disease
aducanumab
Flag link:
FDA looks to pave way for earlier-stage Alzheimer's drugs
FDA looks to pave way for earlier-stage Alzheimer's drugs
Yahoo/Reuters
FDA
Alzheimer's disease
drug development
Flag link:
Biogen tweaks Alzheimer’s phase 3, sparking stock slide
Biogen tweaks Alzheimer’s phase 3, sparking stock slide
Fierce Biotech
Biogen
Alzheimer's disease
clinical trials
aducanumab
Flag link:
Merck scraps another late-stage Alzheimer's drug study
Merck scraps another late-stage Alzheimer's drug study
Yahoo/Reuters
Merck
Alzheimer's disease
verubecestat
Flag link:
Merck just dashed the last remaining hopes for its industry-leading BACE drug for Alzheimer’s
Merck just dashed the last remaining hopes for its industry-leading BACE drug for Alzheimer’s
Endpoints
Merck
BACE inhibitors
Alzheimer's disease
verubecestat
Flag link:
Boehringer ends Alzheimer's research for PDE9 blocker
Boehringer ends Alzheimer's research for PDE9 blocker
Biopharma Dive
Boehringer Ingelheim
Alzheimer's disease
PDE9 blockers
BI 409306
Flag link:
The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease
The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease
Yahoo/Benzinga
Alzheimer's disease
R&D
Flag link:
Namzaric-maker Allergan aims hopeful Alzheimer’s message at caregivers
Namzaric-maker Allergan aims hopeful Alzheimer’s message at caregivers
Fierce Pharma
Namzaric
Allergan
Alzheimer's disease
drug ads
Flag link:
Takeda and Zinfandel write off yet another Alzheimer’s PhIII after Actos fails a key interim test
Takeda and Zinfandel write off yet another Alzheimer’s PhIII after Actos fails a key interim test
Endpoints
Takeda
Zinfandel Pharmaceuticals
Actos
Alzheimer's disease
Flag link:
Eli Lilly finally published its disastrous EXPEDITION3 data, a costly lesson in rethinking Alzheimer’s
Eli Lilly finally published its disastrous EXPEDITION3 data, a costly lesson in rethinking Alzheimer’s
Endpoints
Eli Lilly
clinical trials
Alzheimer's disease
solanezumab
Flag link:

Pages